Investigational drug vupanorsen achieves modest reduction in non-HDL cholesterol
The investigational drug vupanorsen reduced total levels of non-high-density lipoprotein (non-HDL) cholesterol by up to 28% in patients with high cholesterol who were already taking a cholesterol-lowering statin medication, ...
Apr 4, 2022
0
13